A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma-Reference-Cited by-同舟云学术

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

Published:2016-09-20 Issue:1 Volume:4 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Buchbinder Elizabeth I.,Gunturi Anasuya,Perritt Jessica,Dutcher Janice,Aung Sandra,Kaufman Howard L.,Ernstoff Marc S.,Miletello Girald P.,Curti Brendan D.,Daniels Gregory A.,Patel Sapna P.,Kirkwood John M.,Hallmeyer Sigrun,Clark Joseph I.,Gonzalez Rene,Richart John M.,Lutzky Joe,Morse Michael A.,Sullivan Ryan J.,McDermott David F.

Funder

Prometheus

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-016-0155-8

Reference13 articles.

1. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

2. Postow MA, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.

3. Topalian SL, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–30.